MRC-University of Glasgow Centre for Virus Research

Current research

The Thomson lab focuses on the use of next generation sequencing and functional assays to investigate viruses that present a risk to human health in the UK and in Uganda. We work on understanding how viruses evolve under immune pressure and with the use of antiviral treatments. Working with the Clinical Trials Facility in the Queen Elizabeth University Hospital, Professor Emma Thomson is the principal investigator for NHS GG&C for several vaccine trials, including the phase III Oxford/AZ ChAdOx1 vaccine, the Novavax phase III trial, the Valneva phase III trial and the COV-BOOST and DOVE studies.

New and emerging viral infections in the UK

COVID-19

In March 2020, the Thomson lab sequenced the first case of SARS-CoV-2 in Scotland and we have continued to carry out high-scale sequencing in order to monitor introductions of virus variants into the country, for example as a result of international travel. We are currently funded by HDR-UK, COG-UK and the Scottish government to monitor changes in the genome of the virus to vaccine effectiveness. Working with PHS, PHE and other partners, we are members of the Genotype2Phenotype (G2P) consortium, the UK Coronavirus Immunology Consortium (CIC) and ISARIC4C. Our role is to investigate how changes in the genome of the virus may translate to changes in the behaviour of the virus. We have also investigated a number of emerging viruses that have been detected in recent years in the Scottish population, including Ebola virus, Seoul hantavirus and MPOX, amongst others.

In this video, Patawee explains how much we can find out from one single blood sample:

Acute Hepatitis C virus (HCV)

The Thomson group has worked for a number of years on the surveillance of early hepatitis C virus infection in order to understand virus evolution during early infection and the mechanisms behind spontaneous clearance of the virus (up to 50% of infected individuals clear the virus without treatment) in order to advance the search for an effective vaccine. We follow a cohort of more than 200 patients in Glasgow and London who have been identified with early infection and who have been recruited and followed-up regularly following diagnosis. We aim to identify novel B and T cell epitopes recognised during acute HCV infection using next-generation sequencing of the entire genome and functional assays including flow cytometry, ELISpots, neutralisation assays and replicon systems. This project is funded by Wellcome.

In this video, Rajiv explains how blood samples taken from people living with Hepatitis C virus, can help us understand the diversity of the virus and how best to treat it:

New and emerging viral infections in Uganda

Emerging viral infections are an ever-present threat to human and animal health and have often emerged from sub-Saharan Africa. The risk of transmission of viruses to previously unexposed populations has increased as a result of increased global travel, global warming and changes in our ecosystem and human behaviour. In the last 100 years, the emergence of HIV has resulted in at least 35 million deaths while more recently, Zika virus and Ebola virus caused health crises requiring major local and international interventions. Other viral infections (including unidentified infections) remain an unquantified threat to human and animal health. In order to address these risks effectively, major efforts need to be made to improve the infrastructure for identifying risks, developing treatments and vaccines and implementing these interventions in real time.

We are currently using NGS to detect new and emerging viruses in East and West Africa (Uganda) in febrile undiagnosed patients. We are also engaged in improving local diagnostic capacity in the MRC centres in these countries so that undiagnosed new or emerging infections may be detected at source in the future, allowing more rapid control interventions. The CVR provided diagnostic support for the UK response to the Ebola virus outbreak in Sierra Leone (Dr Chris Davis). These emerging viral infection projects have been funded by the MRC, Wellcome, GCRF, UK Rapid Support Team and by the Scottish Research Council.

‌Hepatitis C diversity and response to treatment in sub-Saharan Africa

While Hepatitis C is well characterised in Europe and the United States, the diversity of strains in Africa are quite different and clinical trials have not been carried out in the region. We have recently identified genotypes, rare in Europe but common in Africa that are associated with a reduced response to direct acting antiviral treatments. It will be essential to monitor response to treatment carefully in sub-Saharan Africa in order to achieve the WHO target of elimination by 2030.